Eye protection and supportive care
›Protection and physiology
›Rigid eye shield
›Continuous use
›Removal only by ophthalmology
›Activity restrictions
›Bedrest or limited ambulation
›Avoid bending and straining
›Antiemesis strategy
›Ondansetron IV 4 mg
›Repeat 4 mg every 6 hours as needed
›Max daily dose per local policy
›Metoclopramide IV 10 mg
›Alternative agent
›Avoid in significant QT prolongation risk
›Analgesia strategy
›Fentanyl IV 25 mcg to 50 mcg
›Titration 25 mcg every 5 minutes to comfort
›Respiratory monitoring
›Hydromorphone IV 0.2 mg to 0.5 mg
›Titration 0.2 mg every 10 minutes
›Geriatric dose reduction consideration
Antibiotics for endophthalmitis prophylaxis
›Systemic prophylaxis
›Preferred IV regimen for high-risk open globe
›Vancomycin IV 15 mg/kg
›Max single dose 2 g
›Infusion time at least 60 minutes
›Ceftazidime IV 2 g
›Frequency every 8 hours
›Renal adjustment as needed
›Coverage intent
›Gram-positive including staphylococci
›Gram-negative including Pseudomonas
›Alternative IV regimen when ceftazidime contraindicated
›Vancomycin IV 15 mg/kg
›Same dosing principles
›Monitor infusion reaction
›Ceftriaxone IV 2 g
›Frequency every 24 hours
›Limited Pseudomonas coverage
›Oral option in selected lower-risk cases per ophthalmology
›Levofloxacin PO 750 mg
›Frequency daily
›Tendinopathy risk counseling
›Moxifloxacin PO 400 mg
›Frequency daily
›QT risk consideration
›Timing principle
›Initiate as early as feasible when open globe suspected
›Do not delay for imaging when clinical signs strong (Class I style consensus)
›Immunization management
›Tdap or Td booster
›Indicated if last dose more than 5 years for dirty wound
›Indicated if unknown or incomplete series
›Tetanus immune globulin
›Indicated for unknown or incomplete immunization with contaminated wound
›Separate injection site from vaccine
Operative and ophthalmology-directed therapies
›Specialist-led components
›Primary globe repair
›Corneal or scleral closure
›Uveal tissue repositioning decisions
›Intravitreal antibiotics when indicated
›High contamination risk
›Suspected endophthalmitis
›Corticosteroids selective use
›Inflammation control
›Infection exclusion priority
›Cycloplegia and topical therapies
›Iritis control when appropriate
›Avoid topical pressure increasing maneuvers
›Harm reduction
›Topical drops requiring pressure
›Avoid forced eyelid opening
›Avoid manipulation until protected
›Nasal positive pressure devices when facial fractures suspected
›Orbital emphysema risk
›Worsening orbital pressure risk
›Succinylcholine during induction when alternatives available
›IOP rise concern
›Anesthesia team decision-making